Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients

Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.

Benzinga

Broadcom, Alphabet, Sandisk, Novo Nordisk And Zoom: Why These 5 Stocks Are On Investors' Radars Today

U.S. stock futures rose on Monday, building on Friday’s gains. Optimism is fueled by New York Fed President John Williams‘ suggestion that a December rate cut remains possible.

Benzinga

Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial

The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback. It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Benzinga

Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention drug showed positive results, pushing the share price through the roof.

Euronews

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Report dashes hopes for new use for blockbuster weight-loss drug

The Guardian - UK

The Saturday Spread: Using Data Science to Pick Out the Most Compelling Discounts (NVO, SOFI, FAST)

By leveraging the power of bespoke algorithms, advanced traders can go beyond cookie-cutter finpub content to discover true opportunities.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Weight-Loss Drug Stocks To Consider For 2026

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Benzinga

GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

Fortune

Layoffs are piling up, raising worker anxiety. Here are some companies that have cut jobs recently

It's a tough time for the job market

The Independent UK

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

MarketBeat

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

Novo Nordisk's new pricing for its GLP-1 drugs is a strategic pivot to capture a mass market, pressure rivals, and secure long-term market dominance.

MarketBeat

Novo Nordisk CEO's Bold Vow: Full Commitment to Weight-Loss Pill as Wegovy Price Falls

Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.

International Business Times

With $199 Price, Ozempic Prescriptions Expected to Soar — Experts Warn of Risks

Novo Nordisk's new $199 offer for Ozempic and Wegovy aims to improve access for obesity and diabetes treatments, but experts warn of potential serious side effects.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk Leans Into Affordability Amid Rising Competition

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026.

Benzinga

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control

Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S (NYSE:NVO), saying he intends to strengthen the board's pharmaceutical and over-the-counter expertise while easing concerns about the sweeping power now held by the Novo Nordisk Foundation.

The Independent UK

Price of Wegovy and Ozempic weight loss drugs slashed with certain customers saving $150 per month

A recent poll found that about half of the people who take the treatments say it was hard to afford them

Cycling News

Five-year title sponsor extension solidifies Team Novo Nordisk through 2031

Roster of 20 riders confirmed for 'truly amazing journey' of 15th season for ProTeam comprised of athletes living with diabetes

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Kiplinger

Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know

Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and related conditions.

Benzinga

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

In a presentation at the American Heart Association's (AHA's) 2025 Scientific Sessions, researchers on Tuesday shared data from Novo Nordisk A/S' (NYSE:NVO) Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Benzinga

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Eli Lilly Co. (NYSE:LLY) is reportedly dropping CVS Health Inc.'s (NYSE:CVS) drug benefit plan for its employees.

Euronews

European shares hit record highs on US shutdown progress

European stocks rallied to new record highs as optimism grew over a US government shutdown resolution and strong corporate earnings. Gains were led by healthcare and luxury sectors, while UK bond yields rose amid political uncertainties. Currency and commodity markets showed mixed signals.

Benzinga

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the SP 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 23,468.30.

Benzinga

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.